FrancophonIA/ELRC3.0 huggingface dataset:
English: • after prior platinum-containing chemotherapy, or
Croatian: • koji su prethodno primali kemoterapiju koja je sadržavala platinu, ili
English: Hypersensitivity to atezolizumab or to any of the excipients listed in section 6.1.
Croatian: Preosjetljivost na atezolizumab ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: Median OS for all patient subgroups (PD-L1 expression ≥ 5 % and ≥ 1 %) and in all comers was 10.6 months.
Croatian: Medijan OS-a za sve podskupine bolesnika (ekspresija PD-L1 ≥ 5% i ≥ 1%) i za sve uključene bolesnike iznosio je 10,6 mjeseci.
English: If you miss a dose of Tecentriq
Croatian: Ako ste propustili dozu lijeka Tecentriq
English: The primary analysis of Cohort 2 was performed when all patients had at least 24 weeks of follow-up.
Croatian: Primarna analiza Kohorte 2 provedena je kada su svi bolesnici imali najmanje
English: No reproductive and development toxicity studies have been conducted with atezolizumab; however, based on the 26-week repeat dose toxicity study, atezolizumab had an effect on menstrual cycles at an estimated AUC approximately 6 times the AUC in patients receiving the recommended dose and was reversible (see section 5.3).
Croatian: Nisu provedena ispitivanja reproduktivne i razvojne toksičnosti atezolizumaba; međutim, u 26-tjednom ispitivanju toksičnosti ponovljenih doza atezolizumab je pokazao reverzibilan učinak na menstruacijske cikluse pri procijenjenom AUC-u koji je bio približno 6 puta veći od AUC-a u bolesnika koji su primali preporučenu dozu (vidjeti dio 5.3).
English: Of the 62 patients, two experienced a fatal event.
Croatian: U dva od ta 62 bolesnika zabilježen je smrtni ishod.
English: Patients with event (%) Median (months) (95% CI)
Croatian: Bolesnici s događajem (%) Medijan (mjeseci) (95% CI)
English: Hypothyroidism or hyperthyroidism
Croatian: Hipotireoza ili hipertireoza
English: No data are available in patients with either moderate or severe hepatic impairment.
Croatian: Nema dostupnih podataka o bolesnicima s umjerenim ili teškim oštećenjem jetrene funkcije.
English: There are insufficient data for the subgroup of patients that would be unfit for any chemotherapy; therefore atezolizumab should be used with caution in these patients, after careful consideration of the potential balance of risks and benefits on an individual basis.
Croatian: Nema dovoljno podataka za podskupinu bolesnika koje bi se smatralo nepogodnima za bilo koji oblik kemoterapije, pa u tih bolesnika atezolizumab treba primjenjivati uz oprez, nakon pažljive procjene mogućeg omjera koristi i rizika za svakog pojedinog bolesnika.
English: The schedule of administration must be adjusted to maintain a 3-week interval between doses.
Croatian: Raspored primjene mora se prilagoditi tako da se održi 3-tjedni interval između doza.
English: 14.1 (9.2, NE) 15.9 (10.4, NE)
Croatian: 14,1 (9,2; NP) 15,9 (10,4; NP)
English: • 840 milligrams (mg) every two weeks, or
Croatian: • 840 miligrama (mg) svaka dva tjedna ili
English: • If you do not have an infusion reaction during the first infusion, the next infusions will be given to you over a period of 30 minutes.
Croatian: • Ako tijekom prve infuzije ne doživite reakciju na infuziju, sljedeće ćete infuzije primati tijekom razdoblja od 30 minuta.
English: • decreased number of lymphocyte (a type of white blood cells), which is associated with an increased risk of infection
Croatian: • promjene osjeta okusa (disgeuzija) • smanjen broj limfocita (jedne vrste bijelih krvnih stanica), koji je povezan s povećanim rizikom od infekcije
English: Healthcare professionals are asked to report any suspected adverse reactions the national reporting system listed in Appendix V.
Croatian: Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V.
English: No dose reduction of atezolizumab was allowed.
Croatian: Nije bilo dopušteno smanjivati dozu atezolizumaba.
English: • inflammation of the membrane around the spinal cord and brain
Croatian: • upala membrane oko kralježnične moždine i mozga
English: A population pharmacokinetic analysis indicates that central compartment volume of distribution is 3.28 L and volume at steady-state is 6.91 L in the typical patient.
Croatian: Populacijska farmakokinetička analiza ukazuje na to da u tipičnog bolesnika volumen distribucije u središnji odjeljak iznosi 3,28 l, a volumen u stanju dinamičke ravnoteže 6,91 l.
English: Reminder to educate patients/caregivers about the symptoms of immune-related adverse reactions and of the need to report them immediately to the physician.
Croatian: Podsjetnik da bolesnike/skrbnike treba educirati o simptomima imunološki uzrokovanih nuspojava i upozoriti ih da sve takve nuspojave moraju odmah prijaviti liječniku.
English: (hypoxia)
Croatian: (hipoksija)
English: The median number of treatment cycles was 7 for atezolizumab and 6 for nab-paclitaxel in each treatment arm.
Croatian: Medijan broja ciklusa liječenja atezolizumabom iznosio je 7, a nab-paklitakselom 6 u svakoj liječenoj skupini.
English: 12-month OS (%)*** 18-month OS (%)***
Croatian: 12-mjesečni OS (%)*** 18-mjesečni OS (%)***
English: The maximum systemic accumulation ratio across dosing regimens is 3.3.
Croatian: Omjer maksimalne sistemske akumulacije uz sve režime doziranja iznosi 3,3.
English: The prescriber must discuss the risks of Tecentriq therapy with the patient.
Croatian: Liječnik koji propisuje lijek mora s bolesnikom razgovarati o rizicima liječenja lijekom Tecentriq.
English: • low levels of adrenal hormones
Croatian: • niske vrijednosti hormona nadbubrežne žlijezde
English: Rare nephritisaa
Croatian: Rijetko nefritisaa
English: The use of systemic corticosteroids or immunosuppressants before starting atezolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of atezolizumab.
Croatian: Treba izbjegavati primjenu sistemskih kortikosteroida ili imunosupresiva prije početka liječenja atezolizumabom jer ti lijekovi mogu utjecati na farmakodinamičku aktivnost i djelotvornost atezolizumaba.
English: If you are not sure, talk to your doctor or nurse before you are given Tecentriq.
Croatian: Ako niste sigurni, obratite se svom liječniku ili medicinskoj sestri prije nego primite Tecentriq.
English: From the PD-L1+/BRCA1/2 mutant subgroup, 19 patients received atezolizumab plus nabpaclitaxel and 26 placebo plus nab-paclitaxel.
Croatian: U podskupini s mutacijama PD-L1+/BRCA1/2 19 je bolesnika primalo atezolizumab plus nab-paklitaksel, a njih 26 placebo plus nab-paklitaksel.
English: It is used when this cancer is advanced.
Croatian: Tecentriq se koristi kada je taj rak uznapredovao.
English: For each 28-day cycle, Tecentriq is administered on days 1 and 15, and nab-paclitaxel is administered on days 1, 8, and 15.
Croatian: U svakom 28-dnevnom ciklusu Tecentriq se primjenjuje 1. i 15. dana, a nab-paklitaksel 1., 8. i 15. dana.
English: Incudes reports of hypophysitis and temperature regulation disorder.
Croatian: Uključuje prijavljene slučajeve hipofizitisa i poremećaja regulacije tjelesne temperature.
English: In an exploratory analysis with longer follow up (median: 24.1 months), the median OS for both arms was unchanged relative to the primary analysis, with HR = 0.82 (95% CI: 0.67, 1.01).
Croatian: U eksploracijskoj analizi s duljim praćenjem (medijan: 24,1 mjesec) medijan OS-a za obje skupine ostao je nepromijenjen u odnosu na primarnu analizu, uz HR = 0,82 (95% CI: 0,67; 1,01).
English: However, patients who had prior anti-CTLA-4 treatment could be enrolled, as long as the last dose was received at least 6 weeks prior to randomization, and there was no history of severe immunerelated adverse effects from anti-CTLA-4 (NCI CTCAE Grades 3 and 4).
Croatian: Međutim, mogli su se uključiti bolesnici koji su prethodno primali inhibitore CTLA-4, pod uvjetom da su posljednju dozu primili najmanje 6 tjedana prije randomizacije i da u anamnezi nisu imali teške imunološki uzrokovane nuspojave izazvane primjenom inhibitora CTLA-4 (3. i 4. stupnja težine prema NCI CTCAE kriterijima).
English: The safety of atezolizumab as monotherapy is based on pooled data in 3,178 patients across multiple tumour types.
Croatian: Sigurnost atezolizumaba u monoterapiji temelji se na objedinjenim podacima prikupljenima u 3178 bolesnika s različitim vrstama tumora.
English: No clinically important difference was observed in the pharmacokinetics of atezolizumab among patients < 65 years (n=274), patients between 65−75 years (n=152) and patients > 75 years (n=46) (see section 4.2).
Croatian: Nije primijećena klinički značajna razlika u farmakokinetici atezolizumaba među bolesnicima u dobi od < 65 godina (n=274), bolesnicima u dobi od 65 − 75 godina (n=152) ni bolesnicima u dobi od > 75 godina (n=46) (vidjeti dio 4.2).
English: • have been given medicines to stimulate your immune system
Croatian: • ako ste primili lijekove koji stimuliraju imunosni sustav
English: Patients were randomised (1:1) to receive either atezolizumab or chemotherapy.
Croatian: Bolesnici su bili randomizirani (1:1) za primanje atezolizumaba ili kemoterapije.
English: The key results of this study with a median survival follow-up of 21 months are summarised in Table 10.
Croatian: Ključni rezultati ovog ispitivanja, uz medijan praćenja preživljenja od 21 mjeseca, sažeto su prikazani u Tablici 10.
English: No fertility studies have been conducted with atezolizumab; however assessment of the cynomolgus monkey male and female reproductive organs was included in the chronic toxicity study.
Croatian: Nisu provedena ispitivanja učinka atezolizumaba na plodnost; međutim, ispitivanje kronične toksičnosti uključivalo je ocjenu reproduktivnih organa mužjaka i ženki makaki majmuna.
English: Only a few patients had severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2; n=8) (see section 4.2).
Croatian: Svega je nekoliko bolesnika imalo teško oštećenje bubrežne funkcije (eGFR 15 − 29 ml/min/1,73 m2; n=8) (vidjeti dio 4.2).
English: It is used if: the lung cancer has spread to other parts of the body (extensive-stage) you have not received any prior chemotherapy for extensive-stage SCLC.
Croatian: Tecentriq se koristi: ako se rak pluća proširio u druge dijelove tijela (prošireni stadij) ako prethodno niste primali kemoterapiju za prošireni stadij SCLC-a
English: Patients received treatment until radiographic disease progression per RECIST v1.1, or unacceptable toxicity.
Croatian: Bolesnici su primali liječenje do radiografske progresije bolesti prema verziji 1.1 RECIST kriterija ili do pojave neprihvatljive toksičnosti.
English: Myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome and Meningoencephalitis
Croatian: Mijastenički sindrom/miastenija gravis, Guillain-Barréov sindrom i meningoencefalitis
English: The European Medicines Agency has deferred the obligation to submit the results of studies with atezolizumab in all subsets of the paediatric population in the treatment of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja atezolizumaba u svim podskupinama pedijatrijske populacije za liječenje zloćudnih novotvorina (osim tumora u središnjem živčanom sustavu te novotvorina u hematopoetskom i limfoidnom tkivu) (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Croatian: Unutar iste kategorije učestalosti nuspojave su navedene u padajućem nizu prema ozbiljnosti.
English: To treat extensive-stage SCLC, Tecentriq will be given to you in combination with carboplatin and etoposide.
Croatian: Za liječenje proširenog stadija SCLC-a Tecentriq ćete primati u kombinaciji s karboplatinom i etopozidom.
English: *Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology.
Croatian: *Atezolizumab je humanizirano IgG1 monoklonsko protutijelo na ligand receptora programirane stanične smrti 1 (engl. programmed death ligand 1, PD-L1) proizvedeno Fc-inženjeringom u stanicama jajnika kineskog hrčka tehnologijom rekombinantne DNK.
English: Overall, 41% of enrolled patients had PD-L1 expression ≥1%, 27% had liver metastases and 7% asymptomatic brain metastases at baseline.
Croatian: Ukupno je na početku ispitivanja 41% uključenih bolesnika imalo ekspresiju PD-L1 ≥ 1%, njih 27% imalo je jetrene metastaze, a 7% asimptomatske moždane metastaze.
English: There are no data from the use of atezolizumab in pregnant women.
Croatian: Nema podataka o primjeni atezolizumaba u trudnica.
English: Prior to launch of Tecentriq in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media,
Croatian: Prija stavljanja lijeka Tecentriq u promet u svakoj zemlji članici nositelj odobrenja mora s nacionalnim nadležnim tijelom dogovoriti sadržaj i oblik edukacijskog programa, uključujući komunikacijski medij, način distribucije i sve druge aspekte programa.
English: Grade 4 Diarrhoea or Colitis (life threatening; urgent intervention indicated)
Croatian: Proljev ili kolitis 4. stupnja (opasan po život; indicirana je hitna intervencija)
English: At the time of the updated OS analysis, an exploratory PFS analysis was performed as presented in Table 6.
Croatian: U vrijeme analize ažuriranih podataka o OS-u provedena je i eksploracijska analiza PFS-a kako je prikazano u Tablici 6.
English: Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.
Croatian: Atezolizumab je humanizirano monoklonsko protutijelo imunoglobulin G1 (IgG1) proizvedeno Fc-inženjeringom, koje se vezuje izravno za PD-L1 i ostvaruje dvojnu blokadu receptora PD-1 i B7.1 te tako prekida inhibiciju imunog odgovora posredovanu kompleksom PD-L1/PD-1, što uključuje reaktivaciju imunog odgovora na tumor bez indukcije stanične citotoksičnosti ovisne o protutijelima.
English: The baseline and prognostic disease characteristics of the IMvigor210 Cohort 1 study population were overall comparable to patients in the clinic who would be considered cisplatin ineligible but would be eligible for a carboplatin-based combination chemotherapy.
Croatian: Početne i prognostičke značajke bolesti u populaciji iz Kohorte 1 ispitivanja IMvigor210 sveukupno su bile usporedive s onima u bolesnika iz kliničke prakse koje bi se smatralo nepogodnima za liječenje cisplatinom, ali pogodnima za liječenje kombiniranom kemoterapijom temeljenom na karboplatinu.
English: If you have not received anticancer medicines before for advanced lung cancer, Tecentriq will be given to you in combination with or without bevacizumab and anticancer medicines (chemotherapies called carboplatin and paclitaxel or nab paclitaxel).
Croatian: Ako prethodno niste primali lijekove za uznapredovali rak pluća, Tecentriq ćete primati u kombinaciji s bevacizumabom i drugim lijekovima za rak (kemoterapijskim lijekovima koji se zovu karboplatin i paklitaksel ili nab-paklitaksel) ili bez tih lijekova.
English: Most immune-related adverse reactions occurring during treatment with atezolizumab were reversible with interruptions of atezolizumab and initiation of corticosteroids and/or supportive care.
Croatian: Većina imunološki uzrokovanih nuspojava koje su se javile tijekom liječenja atezolizumabom povukla se uz privremeni prekid primjene atezolizumaba i uvođenje kortikosteroida i/ili potporne skrbi.
English: The demographics and baseline disease characteristics of the study population defined as ITT-WT (n=679) were well balanced between the treatment arms.
Croatian: Demografske i početne značajke bolesti u ispitivanoj populaciji koja se definirala kao ITT populacija s tumorom divljeg tipa (n=679) bile su dobro ujednačene između liječenih skupina.
English: The time to deterioration in other lung cancer symptoms (i.e. cough, dyspnoea, and arm/shoulder pain) as measured by the EORTC QLQ-LC13 was similar between atezolizumab and docetaxel.
Croatian: Vrijeme do pogoršanja drugih simptoma raka pluća (tj. kašlja, dispneje i/ili boli u ruci/ramenu) prema upitniku EORTC QLQ-LC13 bilo je slično uz atezolizumab i uz docetaksel.
English: Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab.
Croatian: Tecentriq je lijek za liječenje raka koji sadrži djelatnu tvar atezolizumab.
English: The key results are summarised in Table 9 and Kaplan-Meier curves for OS and PFS are presented in Figures 6 and 8, respectively.
Croatian: Ključni rezultati sažeto su prikazani u Tablici 9, a Kaplan-Meierove krivulje za OS i PFS prikazane su na Slici 6 odnosno Slici 8.
English: Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.
Croatian: Uključuje prijavljene slučajeve šećerne bolesti, šećerne bolesti tipa 1, dijabetičke ketoacidoze, ketoacidoze.
English: Grade 2: (ALT or AST > 3 to 5 x upper limit of normal [ULN]
Croatian: 2. stupnja: (ALT ili AST > 3 - 5 x iznad gornje granice normale [GGN]
English: The effect of severe renal impairment on the pharmacokinetics of atezolizumab is unknown.
Croatian: Učinak teškog oštećenja bubrežne funkcije na farmakokinetiku atezolizumaba nije poznat.
English: It is recommended that patients are treated with Tecentriq until loss of clinical benefit (see section 5.1) or unmanageable toxicity.
Croatian: Preporučuje se liječiti bolesnike lijekom Tecentriq do gubitka kliničke koristi (vidjeti dio 5.1) ili pojave toksičnosti koja se ne može zbrinuti.
English: Patients were staged according to the American Joint Committee on Cancer (AJCC) 7th edition.
Croatian: Bolesnicima je stadij bolesti bio određen prema 7. izdanju klasifikacije Američkog zajedničkog odbora za rak (engl.
English: Immune system disorders Common infusion-related reactionf Endocrine disorders Very common hypothyroidismg
Croatian: Poremećaji imunološkog sustava Često reakcija na infuzijuf Endokrini poremećaji Vrlo često hipotireoza g
English: Of the 87 patients, one experienced a fatal event.
Croatian: U jednoga od tih 87 bolesnika zabilježen je smrtni ishod.
English: • itching of the skin
Croatian: • svrbež kože
English: Patients who met established criteria and who agreed to be treated beyond disease progression had tumour assessments conducted every 6 weeks until treatment discontinuation.
Croatian: U bolesnika koji su zadovoljavali utvrđene kriterije i koji su pristali na liječenje i nakon progresije bolesti ocjena tumorskog odgovora provodila se svakih 6 tjedana do prekida liječenja.
English: The effect of moderate or severe hepatic impairment (bilirubin > 1.5 × to 3 × ULN and any AST or bilirubin > 3 × ULN and any AST) on the pharmacokinetics of atezolizumab is unknown.
Croatian: Učinak umjerenog ili teškog oštećenja jetrene funkcije (bilirubin > 1,5 - 3 x GGN i bilo koja vrijednost AST-a ili bilirubin > 3 x GGN i bilo koja vrijednost AST-a) na farmakokinetiku atezolizumaba nije poznat.
English: The median age was 55 years (range: 20-86).
Croatian: Medijan dobi iznosio je 55 godina (raspon: 20 - 86).
English: Infections and infestations Very common urinary tract infectiona lung infectionb
Croatian: Infekcije i infestacije Vrlo često infekcija mokraćnih putovaa plućna infekcijab
English: • inflammation of muscles (myositis)
Croatian: • upala mišića (miozitis)
English: The time to deterioration (a sustained ≥ 10-point decline from baseline score) of patient-reported global health status/health-related quality of life as measured by the EORTC QLQ-C30 was similar in each treatment group indicating that all patients maintained their baseline HRQoL for a comparable duration of time.
Croatian: Vrijeme do pogoršanja (održano smanjenje početnog rezultata za ≥ 10 bodova) općeg zdravstvenog statusa/kvalitete života vezane uz zdravlje koje su prijavljivali bolesnici, mjereno upitnikom EORTC QLQ-C30, bilo je slično u obje liječene skupine, što ukazuje na to da su svi bolesnici podjednako dugo održali početnu kvalitetu života vezanu uz zdravlje.
English: • The diluted solution should not be kept more than 24 hours at 2 °C to 8 °C or 8 hours at ambient temperature (≤ 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.
Croatian: • Razrijeđena otopina ne smije se čuvati dulje od 24 sata na temperaturi od 2°C do 8°C ili 8 sati na sobnoj temperaturi (≤ 25°C), osim ako je razrjeđivanje provedeno u kontroliranim i validiranim aseptičnim uvjetima.
English: Elderly Based on a population pharmacokinetic analysis, no dose adjustment of Tecentriq is required in patients ≥ 65 years of age (see sections 4.8 and 5.1).
Croatian: Prema populacijskoj farmakokinetičkoj analizi, nije potrebno prilagođavati dozu lijeka Tecentriq u bolesnika u dobi od ≥ 65 godina (vidjeti dijelove 4.8 i 5.1).
English: • Delay giving your next dose of Tecentriq.
Croatian: • odgoditi primjenu sljedeće doze lijeka Tecentriq
English: • a cancer that arises from the breast, called triple negative breast cancer.
Croatian: • rak koji se razvija u dojci, a zove se trostruko negativan rak dojke.
English: Clinically relevant IRF-assessed ORRs per RECIST v1.1 were shown; however, when compared to a pre-specified historical control response rate of 10%, statistical significance was not reached for the primary endpoint.
Croatian: Zabilježene su klinički relevantne stope ORR-a prema ocjeni neovisnog ocjenjivačkog povjerenstva na temelju verzije 1.1 RECIST kriterija; međutim, kada se one usporede s unaprijed specificiranom kontrolnom stopom odgovora iz prethodnih ispitivanja od 10%, vidljivo je da nije postignuta statistička značajnost za primarnu mjeru ishoda.
English: This is because the effects of Tecentriq in this age group are not known.
Croatian: Naime, nisu poznati učinci lijeka Tecentriq u toj dobnoj skupini.
English: The primary efficacy endpoint for IMvigor211 is overall survival (OS).
Croatian: Primarna mjera ishoda za djelotvornost u ispitivanju IMvigor211 bilo je ukupno preživljenje (engl. overall survival, OS).
English: Based on population PK and exposure-response analyses age (21-89 years), region, ethnicity, renal impairment, mild hepatic impairment, level of PD-L1 expression, or ECOG performance status have no effect on atezolizumab pharmacokinetics.
Croatian: Prema populacijskoj farmakokinetičkoj analizi i analizi podataka o odgovoru na izloženost, dob (21 - 89 godina), regija, etnička pripadnost, oštećenje bubrežne funkcije, blago oštećenje jetrene funkcije, razina ekspresije PD-L1 i funkcionalni ECOG status ne utječu na farmakokinetiku atezolizumaba.
English: Includes reports of musculoskeletal pain and myalgia.
Croatian: Uključuje prijavljene slučajeve mišićno-koštane boli i mialgije.
English: Patients, including those with EGFR mutations or ALK rearrangements, were enrolled and were randomised in a 2:1 ratio to receive one of the treatment regimens described in Table 8.
Croatian: Uključeni bolesnici, uključujući one s EGFR mutacijama ili izmjenama u redoslijedu baza u genu ALK, bili su randomizirani u omjeru 2:1 za primanje jednoga od terapijskih protokola opisanih u Tablici 8.
English: Reminder to distribute the patient alert card to all patients receiving treatment with Tecentriq and to advise them to show it to any healthcare professional who may treat them.
Croatian: Podsjetnik da svim bolesnicima koji primaju Tecentriq treba dati Karticu s upozorenjima za bolesnika i savjetovati im da je pokažu svim zdravstvenim radnicima koji će ih možda liječiti.